Floatz logo

Lorlatinib

Erectile Dysfunction

Fondazione Policlinico Universitario Agostino Gemelli IRCCSSmall moleculeActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

19 Active assets in the Erectile Dysfunction cohort.

Asset / SponsorPhaseRating
Tadalafil
Surgical Outcomes Research Centre (SOuRCe)
Phase 4BB
Sildenafil
The Netherlands Cancer Institute
Phase 4BB
Ningmitai
Xintian Pharmaceutical
Phase 4BB
Indocyanine Green
Ankara University
Phase 4BB
BAY38-9456
Bayer
Phase 4BB

View all 38 →

Same molecule, other indications

Lorlatinib is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
hepatocellular carcinomaDormant
BB
Indicative ·
64 / 100
View asset →
neoplastic meningitisDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →